GALNS and mucopolysaccharidosis type 4A: To evaluate the effect of the GALNS enzyme released by CRISPR/nCas9-edited CD34+ cells, we co-cultured these cells with human MPS IVA fibroblasts for one month and assessed GALNS enzyme activity, along with classical LSD biomarkers.